Status:
TERMINATED
A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Renal Cell Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will examine the effect of treatment with the neoadjuvant antibody pembrolizumab (MK-3475) on tumors of participants with renal cell cancer (RCC). The primary hypotheses are that pembrolizu...
Eligibility Criteria
Inclusion
- Have a newly diagnosed RCC, with a primary tumor diameter of more than 4 cm (\>= T1b), not previously treated, and be a candidate for operative tumor resection
- Be willing and able to undergo pre-treatment baseline image-guided core biopsy of their primary RCC
- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
- Demonstrate adequate organ function
- Female is not breast feeding, is postmenopausal or surgically sterile; demonstrates non-pregnant state, and agrees to use two acceptable methods of birth control throughout the trial, until 120 days after the last dose of treatment
- Male with female partner of childbearing potential agrees to use adequate method of contraception throughout study, until 120 days after last dose of treatment or last blood draw.
Exclusion
- Is currently participating in, or has participated in a study with an investigational agent or device within 4 weeks prior to first dose of study therapy
- Has a diagnosis of immunosuppression or has received systemic steroid therapy, or any other form of immunosuppressive therapy within 4 weeks prior to first dose of study therapy
- Has had prior chemotherapy, targeted small molecule, or radiation therapy for treatment of RCC
- Has a known additional (other than RCC) malignancy that is progressing or requires active treatment
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active, or documented history of autoimmune disease, with the exceptions of vitiligo or resolved childhood asthma/atopy
- Has a history of (non-infectious) pneumonitis that required treatment with steroids or current pneumonitis.
- Has an active infection requiring systematic therapy
- Is receiving anticoagulant therapy, with the exception of low dosage aspirin
- Has severe cardiovascular disease or symptomatic ischemic heart disease
- Has hepatic decompensation
- Has uncontrolled thyroid dysfunction
- Has uncontrolled diabetes mellitus
- Has known psychiatric or substance abuse disorders
- Female is pregnant or breastfeeding
- Is expecting to conceive children within the projected maximum duration of the trial, extending through 120 days after the last dose of treatment or the last blood draw
- Has received prior therapy with any antibody or drug (including ipilimumab) specifically targeting T-cell co-stimulation or checkpoint pathway
- Has a known history of human immunodeficiency virus (HIV)
- Has known active hepatitis B or C
- Has received a live vaccine within 30 days prior to screening
Key Trial Info
Start Date :
December 3 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 5 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02212730
Start Date
December 3 2014
End Date
July 5 2019
Last Update
July 16 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.